RXI Pharma (RXII) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RXi Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Corporate Developments
November 10, 2016 7:02 AM ESTMARLBOROUGH, Mass., Nov. 10, 2016 /PRNewswire/ --Â RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today reported its financial results for the third quarter ended September 30, 2016, and provided a business update.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
"In the third quarter of 2016, RXi has once again been able to keep its cash burn in line with our projections, while continuing the clinical... More
